Literature DB >> 18438612

Primary acquired melanosis with atypia treated with mitomycin C.

Wendy V Anandajeya1, Zélia M Corrêa, James J Augsburger.   

Abstract

The authors report the case of a 56-year-old Caucasian man who was found to have prominent melanotic conjunctival pigmentation inferotemporally in his right eye. Histopathologic evaluation disclosed malignant melanoma of the conjunctiva arising within primary acquired melanosis (PAM) associated with melanocytic atypia. The patient was treated by incisional conjunctival biopsy followed by two cycles of mitomycin C 0.04% eye drops and supplemental double-freeze thaw cryotherapy to residual foci of PAM. By 1 year following this treatment, there was no clinically apparent residual conjunctival melanosis, and visual acuity remained stable at 20/30.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18438612     DOI: 10.1007/s10792-008-9225-3

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  4 in total

Review 1.  Role of topical chemotherapy for primary acquired melanosis and malignant melanoma of the conjunctiva and cornea: review of the evidence and recommendations for treatment.

Authors:  Rajeev Chalasani; Michael Giblin; R Max Conway
Journal:  Clin Exp Ophthalmol       Date:  2006 Sep-Oct       Impact factor: 4.207

2.  The treatment of primary acquired melanosis (PAM) with atypia by topical Mitomycin C.

Authors:  Jacob Pe'er; Joseph Frucht-Pery
Journal:  Am J Ophthalmol       Date:  2005-02       Impact factor: 5.258

3.  Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience.

Authors:  Madhavi Kurli; Paul T Finger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-06-07       Impact factor: 3.117

Review 4.  Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva.

Authors:  F A Jakobiec; R Folberg; T Iwamoto
Journal:  Ophthalmology       Date:  1989-02       Impact factor: 12.079

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.